Recursion Pharmaceuticals (RXRX) Gross Profit (2021 - 2026)

Recursion Pharmaceuticals (RXRX) has 6 years of Gross Profit data on file, last reported at -$6.0 million in Q1 2026.

• Quarterly Gross Profit rose 15.05% year-over-year to -$6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (up 23.3% YoY) and the FY2025 annual result came in at $3.7 million, down 72.59% from the prior year.
• Gross Profit fell to -$6.0 million in Q1 2026, from $21.3 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $21.3 million in Q4 2025 to a low of -$9.5 million in Q3 2025.
• A 5-year average of $286294.1 and a median of -$344000.0 in 2023 frame the typical range for Gross Profit.
• The widest YoY moves for Gross Profit: up 4170.64% in 2024, down 916.63% in 2024.
• Tracing RXRX's Gross Profit over 5 years: stood at $2.8 million in 2022, then plunged by 64.39% to $1.0 million in 2023, then tumbled by 916.63% to -$8.2 million in 2024, then jumped by 357.8% to $21.3 million in 2025, then sank by 128.3% to -$6.0 million in 2026.
• The last three Gross Profit figures came in at -$6.0 million (Q1 2026), $21.3 million (Q4 2025), and -$9.5 million (Q3 2025), per Business Quant data.